What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.82%Above 5Y avg (0.34%)
Annual Rate
CNY 0.32Paid annual
Payout Ratio
54.9%Sustainable
Last Ex-Dividend
Jun 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.53BCNY
1.12B · vs all stocks (USD)
Updated Sep 22, 2026
Trailing P/E
30.89x
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Revenue (TTM)
1.63BCNY
243.13M · vs all stocks (USD)
Updated Sep 22, 2026
Profit Margin
14.58%
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Beta
0.1960x
vs all stocks
Updated Sep 22, 2026
52-Week Change
-46.31%
vs all stocks
Updated Sep 22, 2026
Market Capitalization
7.53BCNY
1.12B · vs all stocks (USD)
Updated Sep 22, 2026
Enterprise Value
8.05BCNY
1.20B · vs all stocks (USD)
Updated Sep 22, 2026
Trailing P/E
30.89x
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Forward P/E
17.28x
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Price to Sales (TTM)
4.47x
vs Medical Instruments & Supplies peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 4.63×.Updated Sep 22, 2026
Price to Book (MRQ)
2.53x
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Enterprise to Revenue
4.94x
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Enterprise to EBITDA
15.97x
vs Medical Instruments & Supplies peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 18.26×.Updated Sep 22, 2026
Gross Margin
61.60%
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Profit Margin
14.58%
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Operating Margin
21.63%
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Return on Assets (TTM)
4.85%
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Return on Equity (TTM)
6.99%
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Revenue (TTM)
1.63BCNY
243.13M · vs all stocks (USD)
Updated Sep 22, 2026
Revenue per Share (TTM)
8.42CNYUpdated Sep 22, 2026
Quarterly Revenue Growth
24.50%
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Gross Profit (TTM)
988.72MCNY
147.59M · vs all stocks (USD)
Updated Sep 22, 2026
EBITDA (TTM)
440.61MCNY
65.77M · vs all stocks (USD)
Updated Sep 22, 2026
Net Income (TTM)
237.46MCNY
35.45M · vs all stocks (USD)
Updated Sep 22, 2026
Quarterly Earnings Growth (YoY)
-22.70%
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Operating Cash Flow (TTM)
335.22MCNY
50.04M · vs all stocks (USD)
Updated Sep 22, 2026
Levered Free Cash Flow (TTM)
-14.66MCNY
-2.19M · vs all stocks (USD)
Updated Sep 22, 2026
Trailing Annual Dividend Rate
0.3200CNYUpdated Sep 22, 2026
Trailing Annual Dividend Yield
0.82%
vs all stocks
Updated Sep 22, 2026
5-Year Average Dividend Yield
0.34%
vs all stocks
Updated Sep 22, 2026
Payout Ratio
54.92%
vs Medical Instruments & Supplies peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 26.23%.Updated Sep 22, 2026
Minority Interest (Equity)
181.49MCNYFY2025 · Dec 31, 2025
Revenue
1.48BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
541.29MCNYFY2025 · Dec 31, 2025
Gross Profit
941.41MCNYFY2025 · Dec 31, 2025
Operating Income
402.96MCNY
60.15M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
289.26MCNYFY2025 · Dec 31, 2025
Income Tax Expense
48.67MCNYFY2025 · Dec 31, 2025
Net Income
240.59MCNYFY2025 · Dec 31, 2025
EBIT
312.25MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
579.49MCNYFY2025 · Dec 31, 2025
Research & Development
95.65MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
206.11MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
20.38MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
3.07MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
22.98MCNYFY2025 · Dec 31, 2025
EPS (Basic)
1.40CNYFY2025 · Dec 31, 2025
EPS (Diluted)
1.40CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
191.55MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
191.55MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
240.59MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
27.58MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
53.57MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-69.54MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
629.81MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
240.59MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
34.08MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-129.39MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-91.72MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-123.11MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-28.03MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.30BCNYFY2025 · Dec 31, 2025
Sale of Investments
1.31BCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-143.96MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
35.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-57.77MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-89.46MCNYFY2025 · Dec 31, 2025
Other Financing Charges
154.81MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
42.58MCNYFY2025 · Dec 31, 2025
Shares Outstanding
193.44MSharesUpdated Sep 22, 2026
Float Shares
142.46MSharesUpdated Sep 22, 2026
% Held by Insiders
33.32%
vs all stocks
Updated Sep 22, 2026
% Held by Institutions
10.71%
vs all stocks
Updated Sep 22, 2026
Total Cash (MRQ)
727.33MCNY
108.57M · vs all stocks (USD)
Updated Sep 22, 2026
Total Cash per Share (MRQ)
3.76CNYUpdated Sep 22, 2026
Total Debt (MRQ)
1.22BCNY
182.77M · vs all stocks (USD)
Updated Sep 22, 2026
Total Debt to Equity (MRQ)
0.3891x
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Current Ratio (MRQ)
3.24x
vs Medical Instruments & Supplies peers
Updated Sep 22, 2026
Book Value per Share (MRQ)
14.92CNYUpdated Sep 22, 2026
Total Assets
3.89BCNY
580.34M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.67BCNYFY2025 · Dec 31, 2025
Total Liabilities
917.65MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
2.22BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
493.89MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
423.75MCNYFY2025 · Dec 31, 2025
Cash
626.37MCNYFY2025 · Dec 31, 2025
Cash Equivalents
3.44MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
629.81MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
166.33MCNYFY2025 · Dec 31, 2025
Accounts Receivable
470.46MCNYFY2025 · Dec 31, 2025
Inventory
313.22MCNYFY2025 · Dec 31, 2025
Accounts Payable
60.03MCNYFY2025 · Dec 31, 2025
Short-term Debt
209.36MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
1.14MCNYFY2025 · Dec 31, 2025
Long-term Debt
370.96MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
16.09MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
193.40MCNYFY2025 · Dec 31, 2025
Retained Earnings
1.15BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.97BCNY
443.37M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
20.04MCNYFY2025 · Dec 31, 2025
52-Week Low
35.23CNYUpdated Sep 22, 2026
52-Week High
76.25CNYUpdated Sep 22, 2026
52-Week Change
-46.31%
vs all stocks
Updated Sep 22, 2026
Beta
0.1960x
vs all stocks
Updated Sep 22, 2026
50-Day MA
40.54CNYUpdated Sep 22, 2026
200-Day MA
49.85CNYUpdated Sep 22, 2026
Avg 10-Day Volume
1.72MSharesUpdated Sep 22, 2026
Avg 30-Day Volume
2.95MSharesUpdated Sep 22, 2026
Diluted EPS (TTM)
1.22CNYUpdated Sep 22, 2026
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Revenue and earnings have both grown steadily across six years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.37: safe zoneNotable
Altman Z-Score: 6.37
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Companies that share the same coordination system — how they create, deliver, or capture value.